{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:57:12Z","timestamp":1791244632933,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.eplepsyres.2019.106165","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T11:21:05Z","timestamp":1562844065000},"page":"106165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Clinical opinion: Earlier employment of polytherapy in sequential pharmacotherapy of epilepsy"],"prefix":"10.1016","volume":"156","author":[{"given":"Byung In","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Eun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2019.106165_bib0005","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40263-017-0471-7","article-title":"Selecting rational drug combinatins in epilepsy","volume":"31","author":"Abou-Khalil","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0010","first-page":"S5","article-title":"Entering a new drug era: practical issues in the treatment of epilepsy","volume":"45","author":"Allen","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0015","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1499-1654.2000.001597.x","article-title":"Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy","volume":"41","author":"Barcs","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0020","first-page":"80","article-title":"Initial development, reliability and validity of a patient-based adverse drug events scale","volume":"35","author":"Baker","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0025","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-94-017-8914-1_24","article-title":"What are the arguments for and against rational therapy for epilepsy?","volume":"813","author":"Barker-Haliski","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","article-title":"Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"16","author":"Baulac","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2003.09.007","article-title":"Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial","volume":"57","author":"Beghi","year":"2003","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0040","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-2125.1997.00607.x","article-title":"The mechanism of the carbamazepine-valproate interaction in humans","volume":"44","author":"Bernus","year":"1997","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1528-1157.1998.tb01356.x","article-title":"Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?","volume":"39","author":"Besag","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0050","series-title":"Epilepsy \u202fSurgery","first-page":"63","article-title":"General concept of medical intractability","author":"Bourgeois","year":"2000"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0055","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/01.WNL.0000103282.62353.85","article-title":"Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy","volume":"62","author":"Boylan","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0060","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.yebeh.2013.03.010","article-title":"When one plus one makes three: the quest for rational antiepileptic polytherapy with supraadditive anticonvulsant efficacy","volume":"27","author":"Brigo","year":"2013","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0065","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11910-016-0678-x","article-title":"Pharmacological treatment of drug-resistant epilepsy in adults: a practical guide","volume":"16","author":"Brodie","year":"2016","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0070","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3182563b19","article-title":"Patterns of treatment response in newly diagnosed epilepsy","volume":"78","author":"Brodie","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0075","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1046\/j.1528-1157.2002.45401.x","article-title":"Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy","volume":"43","author":"Brodie","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0920-1211(98)00110-7","article-title":"Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 study group","volume":"34","author":"Brodie","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0090","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs--rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0100","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 study group","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0105","series-title":"Epilepsy Surgery","first-page":"63","article-title":"General concept of medical intractability","author":"Bourgeois","year":"2000"},{"issue":"Suppl 1","key":"10.1016\/j.eplepsyres.2019.106165_bib0110","first-page":"S29","article-title":"Adjunctive therapy in resistant epilepsy","volume":"29","author":"Callaghan","year":"1988","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1528-1157.1991.tb04670.x","article-title":"Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study","volume":"32","author":"Canadian Clobazam Cooperative Group","year":"1991","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1528-1167.2010.02520.x","article-title":"Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy","volume":"51","author":"Canevini","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0125","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yebeh.2008.02.006","article-title":"Strategies to detect adverse effects of antiepileptic drugs in clinical practice","volume":"13","author":"Carreno","year":"2008","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0130","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.yebeh.2013.10.016","article-title":"Patients\u2019 perspectives on antiepileptic medication: relationships between beliefs about medicines and adherence among patients with epilepsy in UK primary care","volume":"31","author":"Chapman","year":"2014","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0135","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-Year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0140","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/epi.14565","article-title":"Response to treatment schedules after the first antiepileptic drug failed","volume":"59","author":"Chi","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0145","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0150","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1111\/j.1528-1167.2009.02177.x","article-title":"Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study","volume":"50","author":"Cho","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0155","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/epi.13406","article-title":"Drug-resistant epilepsy in adults: outcome trajectories after failure of two medications","volume":"57","author":"Choi","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0160","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/11586830-000000000-00000","article-title":"Examining the clinical utility of lacosamide: pooled analyses of three phase II\/III clinical trials","volume":"24","author":"Chung","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0165","first-page":"527","article-title":"Dosing frequency and medication adherence in chronic disease","volume":"18","author":"Coleman","year":"2012","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0170","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.yebeh.2003.11.031","article-title":"Quality of life improvement with conversion to lamotrigine monotherapy","volume":"5","author":"Cramer","year":"2004","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0175","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.2147\/NDT.S84852","article-title":"Managing drug-resistant epilepsy: challenges and solutions","volume":"12","author":"Dalic","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0180","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(96)90074-4","article-title":"Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy","volume":"347","author":"de Silva","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0185","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00023210-200216030-00002","article-title":"Place of polytherapy in the early treatment of epilepsy","volume":"16","author":"Deckers","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0190","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1528-1157.2000.tb00111.x","article-title":"Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed","volume":"41","author":"Deckers","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-1211(02)00257-7","article-title":"Current limitations of antiepileptic drug therapy: a conference review","volume":"53","author":"Deckers","year":"2003","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0200","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1046\/j.1528-1157.2001.30800.x","article-title":"Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study","volume":"42","author":"Deckers","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0205","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1528-1167.2008.01794.x","article-title":"Impact of nonadherence to antiepileptic drugs on health care utilization and costs","volume":"50","author":"Faught","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0210","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1212\/WNL.0b013e31827b1ae0","article-title":"Depression in epilepsy: a systematic review and meta-analysis","volume":"80","author":"Fiest","year":"2013","journal-title":"Neurology"},{"issue":"Suppl 8","key":"10.1016\/j.eplepsyres.2019.106165_bib0215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2009.02238.x","article-title":"Rational polytherapy","volume":"50","author":"French","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0220","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1212\/01.WNL.0000123693.82339.FC","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0225","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0230","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2174\/157015909788848884","article-title":"Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions","volume":"7","author":"Garnett","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0235","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa0902014","article-title":"Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy","volume":"362","author":"Glauser","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0240","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1212\/WNL.0000000000002791","article-title":"Nonadherence to antiepileptic drugs in Germany: a retrospective, population-based study","volume":"87","author":"Gollwitzer","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0245","series-title":"Clinical Pharmacology of Anti-Epileptic Drugs","first-page":"2","article-title":"Statistical analysis of pharmacokinetic parameters in epileptic patients chronically treated with anti-epileptic drugs","author":"Guelaen","year":"1975"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.yebeh.2015.06.042","article-title":"Depression and anxiety are associated with reduced antiepileptic drug adherence in Chinese patients","volume":"50","author":"Guo","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1136\/jnnp.58.1.44","article-title":"Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial","volume":"58","author":"Heller","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0260","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.seizure.2007.02.011","article-title":"Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients","volume":"16","author":"Heo","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0265","doi-asserted-by":"crossref","first-page":"e2035","DOI":"10.1212\/WNL.0000000000006564","article-title":"Identification of patients who will not achieve seizure remission within 5 years on AEDs","volume":"91","author":"Hughes","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0270","first-page":"RA241","article-title":"Evidence-based medicine: fifteen years later. Golem the good, the bad, and the ugly in need of a review?","volume":"12","author":"Jenicek","year":"2006","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0275","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1528-1167.2008.01713.x","article-title":"Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam","volume":"50","author":"Kaminski","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0280","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.seizure.2017.04.007","article-title":"Psychiatric comorbidities in new onset epilepsy: Should they be always investigated?","volume":"49","author":"Kanner","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0285","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1212\/WNL.0000000000005755","volume":"91","author":"Kanner","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0290","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.55.4.588","article-title":"Adding valproate to lamotrigine: a study of their pharmacokinetic interaction","volume":"55","author":"Kanner","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0295","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","article-title":"Comorbidities of epilepsy: current concepts and future perspectives","volume":"15","author":"Keezer","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ane.12014","article-title":"The impact of epilepsy on patient\u2019s lives","volume":"194","author":"Kerr","year":"2012","journal-title":"Acta Neurol. Scand., Suppl."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0305","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.yebeh.2015.03.005","article-title":"Impact of depression and anxiety on adverse event profiles in Korean people with epilepsy","volume":"46","author":"Kim","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0310","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.seizure.2006.05.001","article-title":"Predicting drug-resistant patients who respond to add-on therapy with levetiracetam","volume":"15","author":"Kinirons","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0315","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0320","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0325","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/seiz.2000.0442","article-title":"Epilepsy after the first drug fails: substitution or add-on?","volume":"9","author":"Kwan","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0330","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1046\/j.1528-1157.2001.04501.x","article-title":"Effectiveness of first antiepileptic drug","volume":"42","author":"Kwan","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0335","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.60.11_suppl_4.S2","article-title":"Clinical trials of antiepileptic medications in newly diagnosed patients with epilepsy","volume":"60","author":"Kwan","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0340","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2165\/00003495-200666140-00004","article-title":"Combination therapy in epilepsy: when and what to use","volume":"66","author":"Kwan","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0345","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1474-4422(11)70154-5","article-title":"Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial","volume":"10","author":"Kwan","year":"2011","journal-title":"Lancet Neurol."},{"issue":"suppl.8","key":"10.1016\/j.eplepsyres.2019.106165_bib0350","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1528-1167.2009.02237.x","article-title":"Refractory seizures; try additional drugs (after two have failed) or go directly to early surgery evaluation?","volume":"50","author":"Kwan","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0355","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1528-1157.1995.tb00484.x","article-title":"Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment","volume":"36","author":"Lammers","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0360","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1734-1140(11)70497-2","article-title":"Basic mechanisms of antiepileptic drugs and their pharmacokinetic\/pharmacodynamic interactions: an update","volume":"63","author":"Lason","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0365","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ane.13025","article-title":"Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis","volume":"139","author":"Lattanzi","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0370","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2017.12.008","article-title":"Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy","volume":"55","author":"Lee","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0375","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.eplepsyres.2018.03.011","article-title":"Comparative efficacy of unique antiepileptic drug regimens in focal epilepsy: an exploratory study","volume":"142","author":"Legge","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0380","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-0404.2009.01182.x","article-title":"Opinion of Belgian neurologists on antiepileptic drug treatment in 2006: belgian study on epilepsy treatment (BESET-2)","volume":"120","author":"Legros","year":"2009","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0385","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ana.21064","article-title":"Results of treatment changes in patients with apparently drug-resistant chronic epilepsy","volume":"62","author":"Luciano","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0390","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.0013-9580.2004.05104.x","article-title":"Preclinical profile of combinations of some second-generation antiepileptic drugs: an isobolographic analysis","volume":"45","author":"Luszczki","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0395","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1528-1167.2011.03075.x","article-title":"Long-term control of epileptic drop attacks with the combination of valproate, lamotrigine, and a benzodiazepine: a\u2019 proof of concept,\u2019 open label study","volume":"52","author":"Machado","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0400","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/jamaneurol.2014.808","article-title":"Effectiveness of antiepileptic drug combination therapy for partial-onset seizures based on mechanisms of action","volume":"71","author":"Margolis","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0405","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0410","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0415","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM199209103271104","article-title":"A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group","volume":"327","author":"Mattson","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0420","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM198507183130303","article-title":"Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures","volume":"313","author":"Mattson","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0425","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archneur.58.8.1264","article-title":"Effect of divalproex-lamotrigine combination therapy in frontal lobe seizures","volume":"58","author":"McCabe","year":"2001","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0430","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.yebeh.2013.05.038","article-title":"Alternative monotherapy or add-on therapy in patients with epilepsy whose seizures do not respond to the first monotherapy: an Italian multicenter prospective observational study","volume":"28","author":"Millul","year":"2013","journal-title":"Epilepsy Behav."},{"issue":"Suppl 8","key":"10.1016\/j.eplepsyres.2019.106165_bib0435","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1528-1167.2009.02235.x","article-title":"Should enzyme-inducing antiepileptic drugs be considered first-line agents?","volume":"50","author":"Mintzer","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0440","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1528-1167.2008.01866.x","article-title":"Lamotrigine-valproic acid combination therapy for medically refractory epilepsy","volume":"50","author":"Moeller","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0445","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1468-1331.2006.01215.x","article-title":"Diagnosing refractory epilepsy: response to sequential treatment schedules","volume":"13","author":"Mohanraj","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0450","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1345\/aph.1E403","article-title":"Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial","volume":"39","author":"Naritoku","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0455","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1136\/bmj.e281","article-title":"Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance","volume":"344","author":"Nunes","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0460","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(16)30294-0","article-title":"Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial","volume":"16","author":"O\u2019Callaghan","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0465","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1528-1157.1989.tb05459.x","article-title":"Phenytoin-induced seizures: a paradoxical effects at toxic concentrations in epileptic patients","volume":"30","author":"Osorio","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0470","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.seizure.2016.12.006","article-title":"Identifying the barriers to antiepileptic drug adherence among adults with epilepsy","volume":"45","author":"O\u2019Rourke","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0475","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-013-0087-0","article-title":"Drug interactions with the newer antiepileptic drugs (AEDs)--part 1: pharmacokinetic and pharmacodynamic interactions between AEDs","volume":"52","author":"Patsalos","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0480","first-page":"55","article-title":"A comparison of clinical practice guidelines in the initial pharmacological management of new-onset epilepsy in adults","volume":"12","author":"Payakachat","year":"2006","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0485","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2125.1996.tb00046.x","article-title":"The new generation of antiepileptic drugs: advantages and disadvantages","volume":"42","author":"Perucca","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"Suppl 4","key":"10.1016\/j.eplepsyres.2019.106165_bib0490","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1046\/j.1528-1157.44.s4.1.x","article-title":"Current trends in antiepileptic drug therapy","volume":"44","author":"Perucca","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0495","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0500","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1684\/epd.2012.0511","article-title":"What clinical trial designs have been used to test antiepileptic drugs and do we need to change them?","volume":"14","author":"Perucca","year":"2012","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0505","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-1211(00)00124-8","article-title":"Assessing risk to benefit ratio in antiepileptic drug therapy","volume":"41","author":"Perucca","year":"2000","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0510","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1528-1157.1998.tb01268.x","article-title":"Antiepileptic drugs as a cause of worsening seizures","volume":"39","author":"Perucca","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0515","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1474-4422(11)70047-3","article-title":"The pharmacological treatment of epilepsy in adults","volume":"10","author":"Perucca","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0520","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1157.1999.tb00832.x","article-title":"The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction","volume":"40","author":"Pisani","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0525","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2016.10.010","article-title":"Association between antiepileptic drug dose and long-term response in patients with refractory epilepsy","volume":"69","author":"Poolos","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0530","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.0b013e31823ed0dd","article-title":"Comparative efficacy of combination drug therapy in refractory epilepsy","volume":"78","author":"Poolos","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0535","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(76)92709-4","article-title":"One drug (phenytoin) in the treatment of epilepsy","volume":"1","author":"Reynolds","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0540","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1528-1157.1981.tb06158.x","article-title":"Phenytoin monotherapy for epilepsy: a long-term prospective study, assisted by serum level monitoring, in previously untreated patients","volume":"22","author":"Reynolds","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0545","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.eplepsyres.2017.02.011","article-title":"Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy","volume":"132","author":"Rhee","year":"2017","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0550","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archneur.1983.04050120047006","article-title":"Valproate-ethosuximide combination therapy for refractory absence seizures","volume":"40","author":"Rowan","year":"1983","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0555","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0560","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0404.2005.00505.x","article-title":"New antiepileptic drugs in practice--how do they perform in the real world?","volume":"181","author":"Sander","year":"2005","journal-title":"Acta Neurol. Scand., Suppl."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0565","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/jnnp.53.11.1008","article-title":"Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy","volume":"53","author":"Sander","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0570","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.phrs.2016.03.016","article-title":"The challenges of treating epilepsy with 25 antiepileptic drugs","volume":"107","author":"Santulli","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0575","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1212\/01.wnl.0000286959.22040.6e","article-title":"Quantifying the response to antiepileptic drugs: effect of past treatment history","volume":"70","author":"Schiller","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0580","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/jnnp.45.12.1119","article-title":"Two antiepileptic drugs for intractable epilepsy with complex-partial seizures","volume":"45","author":"Schmidt","year":"1982","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0585","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1528-1157.1983.tb04900.x","article-title":"Reduction of two-drug therapy in intractable epilepsy","volume":"24","author":"Schmidt","year":"1983","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0590","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0920-1211(02)00065-7","article-title":"The clinical impact of new antiepileptic drugs after a decade of use in epilepsy","volume":"50","author":"Schmidt","year":"2002","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0595","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ana.410190118","article-title":"Alternative single anticonvulsant drug therapy for refractory epilepsy","volume":"19","author":"Schmidt","year":"1986","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0600","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1684\/j.1950-6945.2004.tb00074.x","article-title":"The choice of antiepileptic drugs in newly diagnosed epilepsy: a national French survey","volume":"6","author":"Semah","year":"2004","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0605","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1684\/epd.2014.0650","article-title":"Early add-on treatment vs alternative monotherapy in patients with partial epilepsy","volume":"16","author":"Semah","year":"2014","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0610","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.yebeh.2016.11.018","article-title":"Epilepsy treatment in adults and adolescents: expert opinion, 2016","volume":"69","author":"Shih","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0615","series-title":"Handbook of Epilepsy Treatment","author":"Shorvon","year":"2000"},{"issue":"Suppl 3","key":"10.1016\/j.eplepsyres.2019.106165_bib0620","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1528-1167.2009.02041.x","article-title":"Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958","volume":"50","author":"Shorvon","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1016\/j.eplepsyres.2019.106165_bib0625","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1528-1167.2009.02042.x","article-title":"Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009","volume":"50","author":"Shorvon","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0630","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/bmj.2.6197.1023","article-title":"Reduction in polypharmacy for epilepsy","volume":"2","author":"Shorvon","year":"1979","journal-title":"Br. Med. J."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0635","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1528-1157.1989.tb05326.x","article-title":"Discontinuation of clonazepam after long-term treatment","volume":"30","author":"Specht","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0640","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1684\/j.1950-6945.2004.tb00053.x","article-title":"Antiepileptic drugs: indications other than epilepsy","volume":"6","author":"Spina","year":"2004","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0645","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2174\/157015909788848929","article-title":"Truly \"rational\" polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects","volume":"7","author":"St Louis","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0650","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157015909788848866","article-title":"Antiepileptic drug monotherapy: the initial approach in epilepsy management","volume":"7","author":"St Louis","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0655","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/WCO.0b013e328350ba68","article-title":"Antiepileptic drug monotherapy versus polytherapy: pursuing seizure freedom and tolerability in adults","volume":"25","author":"Stephen","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0660","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.eplepsyres.2011.09.008","article-title":"Antiepileptic drug combinations--have newer agents altered clinical outcomes?","volume":"98","author":"Stephen","year":"2012","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0665","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(05)60613-7","article-title":"Lamotrigine and topiramate may be a useful combination","volume":"351","author":"Stephen","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0670","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1745-6215-8-34","article-title":"Multiple treatment comparisons in epilepsy monotherapy trials","volume":"8","author":"Tudur Smith","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0675","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/clpt.1993.67","article-title":"Effects of felbamate on carbamazepine and its major metabolites","volume":"53","author":"Wagner","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0680","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0278-5846(92)90010-C","article-title":"Methodological requirements for clinical trials in refractory epilepsies--our experience with zonisamide","volume":"16","author":"Yagi","year":"1992","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2019.106165_bib0685","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0404.2006.00705.x","article-title":"Comparison of the efficacy and tolerability of new antiepileptic drugs: what can we learn from long-term studies?","volume":"114","author":"Zaccara","year":"2006","journal-title":"Acta Neurol. Scand."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119302153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121119302153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:41:29Z","timestamp":1760276489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121119302153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":137,"alternative-id":["S0920121119302153"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106165","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical opinion: Earlier employment of polytherapy in sequential pharmacotherapy of epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2019.106165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106165"}}